Food allergy yardstick

IF 5.8 2区医学 Q1 ALLERGY

Annals of Allergy Asthma & Immunology Pub Date : 2025-01-01 DOI:10.1016/j.anai.2024.07.034

Aikaterini Anagnostou MD, PhD , Matthew Greenhawt MD, MBA, MSc , Marcus Shaker MD, MSc , Brian P. Vickery MD , Julie Wang MD

{"title":"Food allergy yardstick","authors":"Aikaterini Anagnostou MD, PhD , Matthew Greenhawt MD, MBA, MSc , Marcus Shaker MD, MSc , Brian P. Vickery MD , Julie Wang MD","doi":"10.1016/j.anai.2024.07.034","DOIUrl":null,"url":null,"abstract":"<div><div>Food allergy management has greatly evolved in the last several years, moving from passive approaches, such as strict food allergen avoidance, to more active treatments, including regulatory approval of the first specifically indicated immunotherapy product (for peanut) in 2020. In 2024, a second therapy, omalizumab, received regulatory approval for the treatment of 1 or more IgE-mediated food allergies, providing clinicians with multiple treatment options to offer patients and families. With this expanded armamentarium of food allergy treatment options, the practicing clinician requires detailed knowledge of benefits and risks of omalizumab, how omalizumab fits into the management landscape, and how to use shared decision-making to optimize therapy. This yardstick aims to provide the clinician with a review of data leading to omalizumab's food allergy indication and an evidence-based expert opinion approach regarding on how best to use this and other therapies available to optimize patient management.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 1","pages":"Pages 110-121"},"PeriodicalIF":5.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1081120624004940","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Food allergy management has greatly evolved in the last several years, moving from passive approaches, such as strict food allergen avoidance, to more active treatments, including regulatory approval of the first specifically indicated immunotherapy product (for peanut) in 2020. In 2024, a second therapy, omalizumab, received regulatory approval for the treatment of 1 or more IgE-mediated food allergies, providing clinicians with multiple treatment options to offer patients and families. With this expanded armamentarium of food allergy treatment options, the practicing clinician requires detailed knowledge of benefits and risks of omalizumab, how omalizumab fits into the management landscape, and how to use shared decision-making to optimize therapy. This yardstick aims to provide the clinician with a review of data leading to omalizumab's food allergy indication and an evidence-based expert opinion approach regarding on how best to use this and other therapies available to optimize patient management.

查看原文本刊更多论文

食物过敏尺度：奥马珠单抗的定位？

在过去的几年里，食物过敏的治疗方法发生了很大的变化，从严格避免食物过敏原等被动方法转变为更积极的治疗方法，包括 2020 年监管部门批准了第一种专门指定的免疫疗法产品（用于花生）。2024 年，第二种疗法奥马珠单抗（omalizumab）获得监管部门批准，用于治疗一种或多种 IgE 介导的食物过敏，为临床医生提供了多种治疗方案，供患者和家属选择。随着食物过敏治疗方案的扩大，执业临床医生需要详细了解奥马珠单抗的益处和风险、奥马珠单抗如何融入治疗方案，以及如何利用共同决策来优化治疗。本指南旨在为临床医生提供有关奥马珠单抗食物过敏适应症的数据回顾，以及以证据为基础的专家意见，说明如何最好地利用该疗法和其他疗法来优化患者管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Allergy Asthma & Immunology 医学-过敏

CiteScore

6.50

自引率

6.80%

发文量

437

审稿时长

33 days

期刊介绍： Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.